Buprenorphine Transdermal System Recalled for Failed Impurity Specifications
AVEVA Drug Delivery Systems recalls nationwide batches of Buprenorphine Transdermal patches due to a degradation impurity exceeding acceptable limits during stability testing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recall with no reported illnesses or injuries. The hazard is a degradation impurity that exceeded specifications during stability testing, constituting a precautionary recall with lower likelihood of adverse health consequences.
Plain-English summary
AVEVA Drug Delivery Systems is recalling Buprenorphine Transdermal System 10 mcg/hour patches distributed nationwide. The recall affects 11,520 cartons with Lot 51835 and expiration date June 2023.
The product failed quality specifications during stability testing. Testing at the 18-month stability timepoint identified the related substance 10-hydroxy buprenorphine N-Oxide at levels exceeding acceptable limits.
Patients currently using buprenorphine patches from this lot should contact their healthcare provider or pharmacist.
The recalled product
- Product
- Buprenorphine Transdermal System, CIII 10 mcg/hour, 4 Transdermal Systems One package of 4 disposal units, Rx Only, Manufactured by: Aveva Drug Delivery Systems Inc. Miramar, FL. 33025, Manufactured for: Apotex Corp Weston, FL. 33326, NDC 60505-7077-05
- Manufacturer
- AVEVA Drug Delivery Systems, Inc.
- Category
- Drug — Transdermal Patch
- Affected units
- 11,520
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot#: 51835 Exp: 06/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by AVEVA Drug Delivery Systems, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · AVEVA Drug Delivery Systems, Inc.
See all →- ModerateRugby nicotine patches exceed impurity specifications during stability testing
FDA (Drugs) · 2026-06-03
- ModerateBuprenorphine Transdermal System 20 mcg/hour Recalled for Specification Failure
FDA (Drugs) · 2023-03-22
Same hazard · degradation impurity
See all →- ModerateAmphetamine extended-release capsules 30 mg recalled after failing impurity specifications
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 10 mg recalled over failed degradation specifications
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 20 mg recalled over impurity and degradation results
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 15 mg recalled after impurity testing failure
FDA (Drugs) · 2025-10-01
- HighEntecavir tablets recalled after failing impurity and degradation specifications
FDA (Drugs) · 2025-09-24